The relationship of Growth differentiation factor-15 with renal damage and dyslipidemia in non-albuminuric and albuminuric Type-2 Diabetes Mellitus

Main Article Content

Hasan Esat Yücel
Bilal İlanbey


Objective: Aim of this study is to investigate the correlation of Growth differentiation factor-15  with renal damage and dyslipidemia in Type-2 Diabetes Mellitus.

Material and Method: The study was conducted prospectively with patients diagnosed with Type-2 Diabetes Mellitus. Two groups were formed as non-albuminuric (n:47) and albuminuric (n:24). Age, gender, Growth differentiation factor-15, glycemic index, lipid panel, glomerular filtration rate, complete blood count, urine albumin/creatin and urine protein/creatin of the groups were compared, and their correlations were examined.

Results: Growth differentiation factor-15, age, and hemoglobin A1c were found to be higher in the albuminuric group, and hemoglobin and hematocrit levels were found to be lower. A positive correlation of Growth differentiation factor-15 with spot urine albumin/creatin and protein/creatin was observed in the albuminuric group. In the non-albuminuric group, positive correlation was observed with Triglyceride and a negative correlation with high-density lipoprotein cholesterol. Negative correlation of Growth differentiation factor-15 glomerular filtration rate was detected in all participants.

Conclusions: Growth differentiation factor-15 has been found positively associated with albuminuria and high triglyceride levels in Type-2 Diabetes Mellitus. It is negatively correlated with glomerular filtration rate and high-density lipoprotein cholesterol. It is strongly associated with renal damage and dyslipidemia.


Download data is not yet available.

Article Details

How to Cite
Yücel, H. E., & İlanbey, B. . (2022). The relationship of Growth differentiation factor-15 with renal damage and dyslipidemia in non-albuminuric and albuminuric Type-2 Diabetes Mellitus. Medical Science and Discovery, 9(6), 334–339.
Research Article
Received 2022-05-24
Accepted 2022-06-09
Published 2022-06-10


Unsicker K, Spittau B, Krieglstein K. The multiple facets of the TGF-β family cytokine growth/differentiation factor-15/macrophage inhibitory cytokine-1. Cytokine Growth Factor Rev. 2013 ;24(4):373-84. DOI:

Wollert KC, Kempf T, Wallentin L. Growth Differentiation Factor 15 as a Biomarker in Cardiovascular Disease. Clin Chem. 2017 ;63(1):140-151. DOI:

Shin MY, Kim JM, Kang YE, Kim MK, Joung KH, Lee JH, et al. Association between Growth Differentiation Factor 15 (GDF15) and Cardiovascular Risk in Patients with Newly Diagnosed Type 2 Diabetes Mellitus. J Korean Med Sci. 2016 ;31(9):1413-8. DOI:

Adela R, Banerjee SK. GDF-15 as a Target and Biomarker for Diabetes and Cardiovascular Diseases: A Translational Prospective. J Diabetes Res. 2015;2015:490842. DOI:

Dostálová I, Roubícek T, Bártlová M, Mráz M, Lacinová Z, Haluzíková D, et al. Increased serum concentrations of macrophage inhibitory cytokine-1 in patients with obesity and type 2 diabetes mellitus: the influence of very low calorie diet. Eur J Endocrinol. 2009 ;161(3):397-404. DOI:

Ding Q, Mracek T, Gonzalez-Muniesa P, Kos K, Wilding J, Trayhurn P, et al.Identification of macrophage inhibitory cytokine-1 in adipose tissue and its secretion as an adipokine by human adipocytes. Endocrinology. 2009 ;150(4):1688-96.

Vergès B. Pathophysiology of diabetic dyslipidaemia: where are we? Diabetologia. 2015;58(5):886-99. DOI:

Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia. 2003 ;46(6):733-49. DOI:

Tziomalos K, Athyros VG, Karagiannis A, Kolovou GD, Mikhailidis DP. Triglycerides and vascular risk: insights from epidemiological data and interventional studies. Curr Drug Targets. 2009 ;10(4):320-7. DOI:

Desmedt S, Desmedt V, De Vos L, Delanghe JR, Speeckaert R, Speeckaert MM. Growth differentiation factor 15: A novel biomarker with high clinical potential. Crit Rev Clin Lab Sci. 2019 ;56(5):333-350. DOI:

Kempf T, Guba-Quint A, Torgerson J, Magnone MC, Haefliger C, Bobadilla M,et al. Growth differentiation factor 15 predicts future insulin resistance and impaired glucose control in obese non-diabetic individuals: results from the XENDOS trial. Eur J Endocrinol. 2012 ;167(5):671-8. DOI:

Carballo-Casla A, García-Esquinas E, Buño-Soto A, Struijk EA, López-García E, et al. Metabolic syndrome and Growth Differentiation Factor 15 in older adults. Geroscience. 2022 ;44(2):867-880. DOI:

Carlsson AC, Nowak C, Lind L, Östgren CJ, Nyström FH, Sundström J, et al. Growth differentiation factor 15 (GDF-15) is a potential biomarker of both diabetic kidney disease and future cardiovascular events in cohorts of individuals with type 2 diabetes: a proteomics approach. Ups J Med Sci. 2020 ;125(1):37-43. DOI:

Chung JO, Chung MY, Park SY, Cho DH, Chung DJ. Relationship between plasma growth differentiation factor-15 level and estimated glomerular filtration rate in type 2 diabetes patients with and without albuminuria. J Diabetes Complications. 2021 ;35(4):107849. DOI:

Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009 5;150(9):604-12. DOI:

Umanath K, Lewis JB. Update on Diabetic Nephropathy: Core Curriculum 2018. Am J Kidney Dis. 2018 ;71(6):884-895 DOI:

Hsiao EC, Koniaris LG, Zimmers-Koniaris T, Sebald SM, Huynh TV, Lee SJ. Characterization of growth-differentiation factor 15, a transforming growth factor beta superfamily member induced following liver injury. Mol Cell Biol. 2000 ;20(10):3742-51. DOI:

Simonson MS, Tiktin M, Debanne SM, Rahman M, Berger B, Hricik D,et al. The renal transcriptome of db/db mice identifies putative urinary biomarker proteins in patients with type 2 diabetes: a pilot study. Am J Physiol Renal Physiol. 2012 1;302(7):F820-9. DOI:

Agarwal RG, Khokhar M, Purohit P, Modi A, Bajpai NK, Bohra GK,et al. A clinical and in-silico study of MicroRNA-21 and growth differentiation factor-15 expression in pre-diabetes, type 2 diabetes and diabetic nephropathy. Minerva Endocrinol (Torino). 2022 Feb 1. Epub ahead of print. DOI:

Simm A, Nass N, Bartling B, Hofmann B, Silber RE, Navarrete Santos A. Potential biomarkers of ageing. Biol Chem. 2008 ;389(3):257-65. DOI:

Bilson J, Scorletti E, Bindels LB, Afolabi PR, Targher G, Calder PC, et al. Growth differentiation factor-15 and the association between type 2 diabetes and liver fibrosis in NAFLD. Nutr Diabetes. 2021 18;11(1):32. DOI:

Li H, Gao F, Xue Y, Qian Y. [Value of plasma growth differentiation factor-15 in diagnosis and evaluation of type 2 diabetic nephropathy]. Nan Fang Yi Ke Da Xue Xue Bao. 2014 ;34(3):387-90. Chinese

Gheith O, Farouk N, Nampoory N, Halim MA, Al-Otaibi T. Diabetic kidney disease: world wide difference of prevalence and risk factors. J Nephropharmacol. 2015 9;5(1):49-56.

Kempf T, Zarbock A, Widera C, Butz S, Stadtmann A, Rossaint J, et al. GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat Med. 2011 ;17(5):581-8. DOI:

Ito K, Yokota S, Watanabe M, Inoue Y, Takahashi K, Himuro N,et al. Anemia in Diabetic Patients Reflects Severe Tubulointerstitial Injury and Aids in Clinically Predicting a Diagnosis of Diabetic Nephropathy. Intern Med. 2021;60(9):1349-1357. DOI:

El-Achkar TM, Ohmit SE, McCullough PA, Crook ED, Brown WW, Grimm R, et al. Kidney Early Evaluation Program. Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: The Kidney Early Evaluation Program. Kidney Int. 2005 ;67(4):1483-8. DOI:

Rabelink TJ, de Zeeuw D. The glycocalyx--linking albuminuria with renal and cardiovascular disease. Nat Rev Nephrol. 2015 ;11(11):667-76. DOI:

Ding Q, Mracek T, Gonzalez-Muniesa P, Kos K, Wilding J, Trayhurn P, et al. Identification of macrophage inhibitory cytokine-1 in adipose tissue and its secretion as an adipokine by human adipocytes. Endocrinology. 2009 ;150(4):1688-96. DOI:

Shimano M, Ouchi N, Walsh K. Cardiokines: recent progress in elucidating the cardiac secretome. Circulation. 2012;20;126(21):e327-32. DOI:

Ho JE, Mahajan A, Chen MH, Larson MG, McCabe EL, Ghorbani A,et al. Clinical and genetic correlates of growth differentiation factor 15 in the community. Clin Chem. 2012 ;58(11):1582-91. DOI:

Grundy SM. Metabolic syndrome update. Trends Cardiovasc Med. 2016 ;26(4):364-73. DOI:

Bermúdez B, López S, Pacheco YM, Villar J, Muriana FJ, Hoheisel JD,et al. Influence of postprandial triglyceride-rich lipoproteins on lipid-mediated gene expression in smooth muscle cells of the human coronary artery. Cardiovasc Res. 2008;15;79(2):294-303. DOI:

Xu X, Li Z, Gao W. Growth differentiation factor 15 in cardiovascular diseases: from bench to bedside. Biomarkers. 2011;16(6):466-75. DOI:

Kim JM, Back MK, Yi HS, Joung KH, Kim HJ, Ku BJ. Effect of Atorvastatin on Growth Differentiation Factor-15 in Patients with Type 2 Diabetes Mellitus and Dyslipidemia. Diabetes Metab J. 2016 ;40(1):70-8. DOI: